SCHEMBL7589602

SCHEMBL7589602

CC1=CC(O)CC(c2cccc(Cl)c2)N1C

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.45
MAOA P21397 4/20 0.43
MAOB P27338 4/20 0.43
RIPK1 Q13546 1/20 0.40
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
PDE5A O76074 1/20 0.38
MDM2 Q00987 2/20 0.38
SLC9A1 P19634 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
PRKCZ Q05513 1/20 0.36
HTT P42858 1/20 0.36
HSD17B2 P37059 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7589609 1.00 CHRNA7 (0.45) CHRNA7MAOAMAOBRIPK1SLC6A2
SCHEMBL7684879 0.81 RIPK1 (0.42) CHRNA7MAOAMAOBRIPK1PDE5A
SCHEMBL7684882 0.81 RIPK1 (0.42) CHRNA7MAOAMAOBRIPK1PDE5A
SCHEMBL6985269 0.71 CHRNA7 (0.45) CHRNA7MAOAMAOBRIPK1SLC6A2
SCHEMBL7590850 0.70 MAOA (0.44) CHRNA7MAOAMAOBRIPK1SLC6A2
SCHEMBL7694164 0.70 MAOA (0.44) CHRNA7MAOAMAOBRIPK1SLC6A2
SCHEMBL7694161 0.70 MAOA (0.44) CHRNA7MAOAMAOBRIPK1SLC6A2
SCHEMBL7595212 0.70 MAPT (0.40) SLC6A2SLC6A3SLC9A1HTR2AHTR2C
SCHEMBL7595211 0.70 MAPT (0.40) SLC6A2SLC6A3SLC9A1HTR2AHTR2C
SCHEMBL24775407 0.65 CHRNB2 (0.64) CHRNA7MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6451789-B1 CENTRAL NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS LES LABORTOIRES SERVIER (FR) 2002-09-17 US disclosed
US-20020042413-A1 1-aza-2-alkyl-6-aryl-cycloalkanes RAULT SYLVAIN (FR) 2002-04-11 US disclosed
US-6323222-B1 COGNITION ACTIVATORS, ALZHEIMER*S DISEASE AND ENZYME INHIBITORS ADIR ET COMPAGNIE (FR) 2001-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042413-A1 1-aza-2-alkyl-6-aryl-cycloalkanes SULT2A1, GRIN2A, NR3C1 CHRNA7 150/4885MAOA 468/4885MAOB 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.